 |
|
|
| |
Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients With Documented Lamivudine Resistance (LAM-R)
|
| |
| |
Reported by Jules Levin
APASL 2013, Singapore
Scott Fung1, Peter Kwan,2 Andrzej Horban3, Mijomir Pelemis4, Petr Husa5, Hie-Won Hann6, John F. Flaherty7, Benedetta Massetto7, Phillip Dinh7, Amoreena Corsa7, Kathryn Kitrinos7, John G. McHutchison7, Milotka Fabri8, Edward Gane9
1Toronto General Hospital, Toronto, Ontario, Canada; 2University of British Columbia, Vancouver, BC, Canada; 3Medical University of Warsaw, Warsaw, Poland; 4Clinic for Infectious and Tropical Diseases, Belgrade, Serbia;
5Faculty Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic, 6Thomas Jefferson University, Philadelphia, PA, USA; 7Gilead Sciences, Inc., Foster City, CA, USA; 8Clinic for Infectious Diseases, Novi Sad, Serbia; 9Auckland General Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
